Role of 5-HT(2A) receptor antagonists in the treatment of insomnia

por Vanover, Kimberly E, Davis, Robert E
Publicado 2010

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, 
Present and Future

por Li, Peng, Snyder, Gretchen L., Vanover, Kimberly E.
Publicado 2016

F250. DEPRESSION IN SCHIZOPHRENIA: CORRELATIONS WITH OBJECTIVE AND SUBJECTIVE QUALITY OF LIFE OUTCOMES

por Harvey, Philip, Vanover, Kimberly, Davis, Robert, Penn, David, Pinkham, Amy
Publicado 2018

S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED...

por Vanover, Kimberly, Davis, Robert, Durgam, Suresh, Huo, Jason, Mates, Sharon, Satlin, Andrew, Harvey, Philip D
Publicado 2020

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS

por Durgam, Suresh, Satlin, Andrew, Davis, Robert E, Vanover, Kimberly E, Mates, Sharon, Kane, John M
Publicado 2020

M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY

por Satlin, Andrew, Durgam, Suresh, Vanover, Kimberly E, Davis, Robert E, Huo, Jason, Mates, Sharon, Correll, Christoph
Publicado 2020

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

por Kane, John M, Durgam, Suresh, Satlin, Andrew, Vanover, Kimberly E, Chen, Richard, Davis, Robert, Mates, Sharon
Publicado 2021

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

por Davis, Robert, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Vanover, Kimberly
Publicado 2018

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

por Vanover, Kimberly, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Davis, Robert
Publicado 2018

Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

por Vanover, Kimberly E., Davis, Robert E., Zhou, Yun, Ye, Weiguo, Brašić, James R., Gapasin, Lorena, Saillard, Jelena, Weingart, Michal, Litman, Robert E., Mates, Sharon, Wong, Dean F.
Publicado 2018

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

por Correll, Christoph U., Davis, Robert E., Weingart, Michal, Saillard, Jelena, O’Gorman, Cedric, Kane, John M., Lieberman, Jeffrey A., Tamminga, Carol A., Mates, Sharon, Vanover, Kimberly E.
Publicado 2020

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

por Snyder, Gretchen L., Prickaerts, Jos, Wadenberg, Marie-Louise, Zhang, Lei, Zheng, Hailin, Yao, Wei, Akkerman, Sven, Zhu, Hongwen, Hendrick, Joseph P., Vanover, Kimberly E., Davis, Robert, Li, Peng, Mates, Sharon, Wennogle, Lawrence P.
Publicado 2016

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

por Snyder, Gretchen L., Vanover, Kimberly E., Zhu, Hongwen, Miller, Diane B., O’Callaghan, James P., Tomesch, John, Li, Peng, Zhang, Qiang, Krishnan, Vaishnav, Hendrick, Joseph P., Nestler, Eric J., Davis, Robert E., Wennogle, Lawrence P., Mates, Sharon
Publicado 2014